Patient-derived organoids (PDOs): a novel preclinical platform to overcome challenges in cancer immunotherapy
Dongmei Ni(Shanghai Construction Group (China)), Xiaolan Yin(Shanghai Construction Group (China)), Qinghe Zhou(Jiaxing University), Junjie Xing(Second Military Medical University), Jingjing Qiu(Institute for Biomedicine), Gengming Niu(Institute for Biomedicine), Guiying Wei(Institute for Biomedicine), Gang Chen(Wuhan University)
Cited by 1
Related Papers
Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma
|Acta Biochimica et Biophysica Sinica|2017|148
Single‐cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer
|Immunology|2022|136
GABRD promotes progression and predicts poor prognosis in colorectal cancer
|Open Medicine|2020|42
Overexpression of FNDC1 in Gastric Cancer and its Prognostic Significance
|Journal of Cancer|2018|41
Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR
|The FASEB Journal|2023|41